H.C. Wainwright lowered the firm’s price target on Beam Global (BEEM) to $8 from $30 and keeps a Buy rating on the shares. The firm says its lower target reflects the lower-than-expected revenue ...
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best emerging technology stocks to buy right now. The company develops precision genetic medicines using base editing, a next-generation approach ...
On Monday, H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback